Straits Times Index
3,322.81 -3.47 (-0.10%) Nikkei
39,701.18 +528.03 (+1.35%) Hang Seng
18,107.87 +34.97 (+0.19%) FTSE 100
8,247.79 -33.76 (-0.41%) Bitcoin USD
61,546.14 +578.71 (+0.95%) CMC Crypto 200
1,278.93 -4.86 (-0.38%)
ARWR Sep 2024 35.000 call
| Previous close | 1.3000 |
| Open | 1.3000 |
| Bid | 0.6000 |
| Ask | 1.3000 |
| Strike | 35.00 |
| Expiry date | 2024-09-20 |
| Day's range | 1.3000 - 1.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | 10.76k |
Business WireArrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial
PASADENA, Calif., June 25, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced plans to advance investigational plozasiran into a Phase 3 cardiovascular outcomes trial called CAPITAN. This comes after promising results were recently announced from multiple clinical trials in three distinct patient populations, including the pivotal Phase 3 PALISADE study in patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome (FCS), the Phase 2 SHASTA-2 s
Business WireArrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE
PASADENA, Calif., June 24, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that preclinical data on ARO-INHBE, an investigational RNAi-based medicine for the treatment of obesity and metabolic diseases, were presented at the American Diabetes Association (ADA) 84th Scientific Sessions, which were held June 21-24, in Orlando, FL, and virtually.
BenzingaWhy Is Arrowhead Pharmaceuticals Stock Trading Higher On Monday?
On Monday, Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) released topline results from the Phase 3 PALISADE study of plozasiran in patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome (FCS). FCS is a rare metabolic disease that prevents the body from digesting fats. Related: What Arrowhead Pharmaceutical’s Interim Data Reveals About A RNAi Therapeutic For Rare Cholesterol Disorder The study met the primary endpoint of lowering triglycerides and all key sec
